Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Pathogen safety of Beriate®.

Gröner A.

Thromb Res. 2014 Nov;134 Suppl 1:S10-5. doi: 10.1016/j.thromres.2013.10.013. Epub 2014 Apr 13. Review.

PMID:
24726555
2.

Pathogen safety of plasma-derived products - Haemate P/Humate-P.

Gröner A.

Haemophilia. 2008 Nov;14 Suppl 5:54-71. doi: 10.1111/j.1365-2516.2008.01852.x. Review.

PMID:
18786011
3.

Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia A.

Klamroth R, Gottstein S, Orlovic M, Heinrichs C.

Thromb Res. 2014 Nov;134 Suppl 1:S38-42. doi: 10.1016/j.thromres.2013.10.015. Epub 2013 Nov 17.

PMID:
24256767
4.

Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.

Klamroth R, Gröner A, Simon TL.

Transfusion. 2014 May;54(5):1406-17. doi: 10.1111/trf.12423. Epub 2013 Sep 30. Review.

PMID:
24117799
5.
6.

Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.

Furuya K, Murai K, Yokoyama T, Maeno H, Takeda Y, Murozuka T, Wakisaka A, Tanifuji M, Tomono T.

Vox Sang. 2006 Aug;91(2):119-25.

PMID:
16907872
7.

Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.

Klamroth R, Holzhauer S, Zimmermann R, Heller C, Kurnik K; Beriate® Pharmacovigilance Group.

Thromb Res. 2014 Nov;134 Suppl 1:S16-21. doi: 10.1016/j.thromres.2013.10.014. Epub 2014 Jan 10.

PMID:
24418255
8.

Pathogen safety of human C1 esterase inhibitor concentrate.

Gröner A, Nowak T, Schäfer W.

Transfusion. 2012 Oct;52(10):2104-12. doi: 10.1111/j.1537-2995.2012.03590.x. Epub 2012 Mar 13.

PMID:
22413956
9.

Prospective study of continuous infusion with Beriate® P in patients with severe haemophilia A undergoing surgery - a subgroup analysis.

Auerswald G, Bade A, Johne J, Haubold K, Overberg D, Masurat S, Moorthi C.

Thromb Res. 2014 Nov;134 Suppl 1:S43-7. doi: 10.1016/j.thromres.2013.10.009. Epub 2013 Dec 21.

PMID:
24360932
10.

[Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].

Ristol P, Gensana M, Fernández J, Massot M, Biescas H, Darling A, Jorquera JI, Vericat F.

Sangre (Barc). 1996 Apr;41(2):131-6. Spanish.

PMID:
9045353
11.

Twenty years of treatment with Beriate® P.

Brackmann HH.

Thromb Res. 2014 Nov;134 Suppl 1:S1-3. doi: 10.1016/j.thromres.2013.10.011. Epub 2013 Dec 21. No abstract available.

PMID:
24360930
12.

Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes.

Farcet MR, Lackner C, Antoine G, Rabel PO, Wieser A, Flicker A, Unger U, Modrof J, Kreil TR.

Transfusion. 2016 Feb;56(2):383-91. doi: 10.1111/trf.13343. Epub 2015 Sep 24.

PMID:
26399175
13.

Safety procedures of coagulation factors.

Jorquera JI.

Haemophilia. 2007 Dec;13 Suppl 5:41-6. doi: 10.1111/j.1365-2516.2007.01578.x.

PMID:
18078396
14.

Assessment of needs for plasma for fractionation in Europe.

Burckhardt JJ.

Biologicals. 1999 Dec;27(4):337-41.

PMID:
10686061
16.

A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.

Poelsler G, Berting A, Kindermann J, Spruth M, Hämmerle T, Teschner W, Schwarz HP, Kreil TR.

Vox Sang. 2008 Apr;94(3):184-92. doi: 10.1111/j.1423-0410.2007.01016.x. Epub 2007 Dec 19.

PMID:
18167162
17.

Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.

Terpstra FG, Parkkinen J, Tölö H, Koenderman AH, Ter Hart HG, von Bonsdorff L, Törmä E, van Engelenburg FA.

Vox Sang. 2006 Jan;90(1):21-32.

PMID:
16359352
18.

Treatment of haemophilia patients in East Germany prior to and after reunification in 1990.

Lenk H.

Thromb Res. 2014 Nov;134 Suppl 1:S57-60. doi: 10.1016/j.thromres.2013.10.018. Epub 2014 Apr 16. Review.

PMID:
24745720
19.

Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.

Kreil TR, Wieser A, Berting A, Spruth M, Medek C, Pölsler G, Gaida T, Hämmerle T, Teschner W, Schwarz HP, Barrett PN.

Transfusion. 2006 Jul;46(7):1143-51.

PMID:
16836561
20.

Challenges for new haemophilia products from a manufacturer's perspective.

Schulte S.

Thromb Res. 2014 Nov;134 Suppl 1:S72-6. doi: 10.1016/j.thromres.2013.10.021. Epub 2013 Dec 21. Review.

PMID:
24360931

Supplemental Content

Support Center